(Q30357011)

English

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati (English)

1 reference

Europe PubMed Central

18 August 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

François Guilhot

object named as

François Guilhot

3

0 references

object named as

Brian J Druker

4

0 references

Hagop Kantarjian

18

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

18 August 2017

Michele Baccarani

2

object named as

Michele Baccarani

1 reference

Europe PubMed Central

18 August 2017

Jorge Eduardo Cortes

1

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

18 August 2017

7

object named as

Fabrizio Pane

1 reference

Europe PubMed Central

18 August 2017

15

object named as

Marc Rudoltz

1 reference

Europe PubMed Central

18 August 2017

Jerald P Radich

19

object named as

Jerald P Radich

1 reference

Europe PubMed Central

18 August 2017

5

object named as

Susan Branford

1 reference

Europe PubMed Central

18 August 2017

Ricardo Pasquini

8

object named as

Ricardo Pasquini

1 reference

Europe PubMed Central

18 August 2017

Matt E Kalaycio

10

object named as

Matt Kalaycio

1 reference

Europe PubMed Central

18 August 2017

Beatriz Moiraghi

11

object named as

Beatriz Moiraghi

1 reference

Europe PubMed Central

18 August 2017

author name string

Dong-Wook Kim

6

1 reference

Europe PubMed Central

18 August 2017

Stuart L Goldberg

9

1 reference

Europe PubMed Central

18 August 2017

Jacob M Rowe

12

1 reference

Europe PubMed Central

18 August 2017

Elena Tothova

13

1 reference

Europe PubMed Central

18 August 2017

Carmino De Souza

14

1 reference

Europe PubMed Central

18 August 2017

Richard Yu

16

1 reference

Europe PubMed Central

18 August 2017

Tillmann Krahnke

17

1 reference

Europe PubMed Central

18 August 2017

Timothy P Hughes

20

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

14 December 2009

1 reference

Europe PubMed Central

18 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

18 August 2017

28

1 reference

Europe PubMed Central

18 August 2017

424-430

1 reference

Europe PubMed Central

18 August 2017

3

1 reference

Europe PubMed Central

18 August 2017

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Staging and prognosis in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

3 June 2018

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4979244

26 November 2018

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20008622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.25.3724

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30357011&oldid=1955416099"